

## State of Oklahoma SoonerCare

Besremi<sup>®</sup> (Ropeginterferon Alfa-2b-njft) Prior Authorization Form

Member Name:	Date of Birth:	_ Member ID#:	
Drug Information			
Pharmacy Billing (NDC:	) Start Date (or date of	f next dose):	
Dose:	Regimen:		
Billing Provider Information			
Pharmacy NPI:	Pharmacy Name:		
Pharmacy Phone:	Pharmacy Fax:		
Prescriber Information			
Prescriber NPI:	Prescriber Name:		
Prescriber Phone:	Prescriber Fax:	Specialty:	
Criteria			
For Initial Authorization: 1. Please indicate the diagnosis and information:			

- Polycythemia Vera
- A. Will Besremi<sup>®</sup> be used as a single agent? Yes\_\_\_\_ No\_\_\_\_
  If diagnosis is not listed above, please indicate diagnosis:\_\_\_\_\_\_

Additional Information:

## For Continued Authorization:

- Date of last dose:
   Does member have any evidence of progressive disease while on Besremi<sup>®</sup> ? Yes\_\_\_\_ No\_\_\_\_
- 3. Has the member experienced adverse drug reactions related to Besremi<sup>®</sup> therapy? Yes No

If yes, please specify adverse reactions:\_\_\_\_\_

Additional Information:

Prescriber Signature:\_\_\_\_\_ Date:\_\_\_\_\_ Date:\_ the best of my knowledge. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error,
Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

11/23/2022